• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Email alerts

 

Section: Investors

  • The financial year in review to March 2021
  • The financial year in review to March 2020
  • The financial year in review to March 2019
  • Email alerts
  • General Meetings
  • Investor Centre
  • Share Price Information
  • Analyst Research
  • Corporate Governance
  • Advisors
  • Webcasts and Presentations
  • Financial Reports
  • Financial Calendar
  • Major Shareholdings
  • RNS Notifications
  • Documents and Circulars
  • Declarations

Subscribe here for our Press Releases:

The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: 

© ReNeuron Group plc 2022 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer